Printer Friendly

MARK SKALETSKY NAMED PRESIDENT AND CEO OF GELTEX INC.

 LEXINGTON, Mass. May 5 /PRNewswire/ -- GelTex Inc. announced today the appointment of Mark Skaletsky as president and chief executive officer. Skaletsky joins GelTex after more than 10 years in senior executive positions at Enzytech, Inc., Biogen, Inc. and Opta Food Ingredients, Inc.
 GelTex is a recently established biotechnology company that is developing orally administered therapeutic products that act by binding to and removing harmful substances through the gastrointestinal tract. The company's approach combines molecular recognition technology with polymer science.
 "Mark Skaletsky brings to GelTex a wealth of expertise and an outstanding record of achievement in building and managing biotechnology companies," said Robert J. Carpenter, chairman of the board of GelTex and company founder. "We are pleased he has joined our effort to develop and commercialize this new class of pharmaceuticals based on therapeutic polymers."
 Skaletsky is chairman of the board of Opta Food Ingredients and served as chairman of the board of Enzytech until February 1993, when Enzytech was acquired by Alkermes, Inc. Prior to Enzytech, which he joined in 1988, Skaletsky served for five years as president and chief operating officer of Biogen. Skaletsky is also currently a director of ISIS Pharmaceuticals, Inc.
 Based in Lexington, GelTex was founded in 1992 by Carpenter, former executive vice president of Genzyme Corporation, and chairman and chief executive officer of Integrated Genetics; George Whitesides, Ph.D., Mallinckrodt Professor of Chemistry at Harvard University; Henry Blair, a cofounder of Genzyme; and James Tananbaum, M.D., currently employed at Merck.
 -0- 5/5/93
 /CONTACT: Mark Skaletsky, president and CEO of GelTex Inc., 617-863-1720, or Robert Gottlieb, senior VP of Feinstein Partners, 617-577-8110, for GelTex/


CO: GelTex Inc. ST: Massachusetts IN: MTC SU: PER

AK -- NE003 -- 4701 05/05/93 08:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1993
Words:289
Previous Article:MAJOR CABLE PROGRAMMERS SIGN WITH DIRECTV(TM); GM HUGHES UNIT TO NATIONALLY DISTRIBUTE TBS, USA NETWORK, SCI-FI, TNN, CMT, FAMILY CH.
Next Article:BROOKLYN UNION SUBSIDIARY ACQUIRES EXXON WELLS IN ARKOMA BASIN
Topics:


Related Articles
ENZYTECH APPOINTS HAYS AS PRESIDENT AND CEO
Mark Skaletsky Elected to Leukosite Board of Directors
GelTex Pharmaceuticals Announces Acquisition of SunPharm Corporation.
SunPharm Corporation To Merge With GelTex Pharmaceuticals, Inc.
GelTex Pharmaceuticals Completes Acquisition of SunPharm Corporation.
Genzyme and GelTex Say Study Highlights Risks of Calcium for Dialysis Patients.
Genzyme General to Acquire GelTex Pharmaceuticals.
GelTex Pharmaceuticals Reports Third Quarter 2000 Results.
Genzyme and GelTex Announce Filing of Registration Statement for Genzyme's Acquisition of GelTex.
Paradigm Genetics Appoints Mark Skaletsky to Its Board of Directors.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters